These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 10451932)

  • 21. [Complication of percutaneous coronary intervention--coronary dissection and acute closure].
    Mitsudo K
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():518-23. PubMed ID: 12735026
    [No Abstract]   [Full Text] [Related]  

  • 22. Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model.
    Lynch JJ; Sitko GR; Lehman ED; Vlasuk GP
    Thromb Haemost; 1995 Aug; 74(2):640-5. PubMed ID: 8585000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prevention of thrombosis in the after-care of coronary dilatation and thrombolysis].
    Weber MA; Lorenz RL; Schramm W; Theisen K
    Z Kardiol; 1986; 75 Suppl 5():107-11. PubMed ID: 2950673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
    Shebuski RJ; Smith JM; Storer BL; Granett JR; Bugelski PJ
    J Pharmacol Exp Ther; 1988 Aug; 246(2):790-6. PubMed ID: 3136245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antithrombin and thrombolytic effects of a new antithrombin agent: angioscopic and angiographic comparison with heparin or batroxobin.
    Tomaru T; Nakamura F; Miwa AY; Fujimori Y; Omata M; Okada R; Uchida Y
    J Interv Cardiol; 1994 Oct; 7(5):409-19. PubMed ID: 10155190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. I. Adjunctive therapy with monoclonal antibody 7E3 F(ab')2 fragment.
    Rote WE; Mu DX; Bates ER; Nedelman MA; Lucchesi BR
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):194-202. PubMed ID: 7511747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stent thrombosis--risk assessment and prevention.
    Motovska Z; Knot J; Widimsky P
    Cardiovasc Ther; 2010 Oct; 28(5):e92-100. PubMed ID: 20553282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double vessel occlusions after balloon angioplasty treated by stenting and subsequently by abciximab infusion.
    Bertrand OF; Meerkin D; de Guise P; Crépeau J; Bourassa MG
    Can J Cardiol; 2000 Jan; 16(1):83-5. PubMed ID: 10653937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Pieper K; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2001 Nov; 142(5):790-8. PubMed ID: 11685164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Batroxobin plus aspirin reduces restenosis after angioplasty for arterial occlusive disease in diabetic patients with lower-limb ischemia.
    Wang J; Zhu YQ; Li MH; Zhao JG; Tan HQ; Wang JB; Liu F; Cheng YS
    J Vasc Interv Radiol; 2011 Jul; 22(7):987-94. PubMed ID: 21570870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hematocrit as an indicator for coronary intervention in patients with acute myocardial infarction].
    Inoue F; Hashimoto T; Tabuse H; Saito Y
    J Cardiol; 2003 Dec; 42(6):241-7. PubMed ID: 14723016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Can coronary "restenosis" after percutaneous angioplasty be prevented?].
    Juliard JM; Himbert D; Steg PG
    Presse Med; 1992 Feb; 21(4):149-52. PubMed ID: 1532070
    [No Abstract]   [Full Text] [Related]  

  • 34. Catastrophic thrombus development despite systemic heparinization during coronary angioplasty: possible relationship to nonionic contrast.
    Doorey AJ; Stillabower ME; Gale N; Goldenberg EM
    Clin Cardiol; 1992 Feb; 15(2):117-20. PubMed ID: 1737403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Percutaneous intervention: design, technique, and pharmacology.
    Linnemeier TJ
    Cathet Cardiovasc Diagn; 1998 Jul; 44(3):265-6. PubMed ID: 9676793
    [No Abstract]   [Full Text] [Related]  

  • 36. Experience of extensive vascular surgery on defibrase-defibrinogenated patients.
    Olsson P; Blombäck M; Egberg N; Ekeström S
    Thromb Res; 1976 Sep; 9(3):277-87. PubMed ID: 982350
    [No Abstract]   [Full Text] [Related]  

  • 37. Adjunctive Therapy with an Antithrombotic Drug Can Prevent Reocclusion and Induce Residual Thrombus Reduction After Percutaneous Transcatheter Angioplasty of the Thrombotic Lesions.
    Kawano H; Tomaru T; Omata M; Okada R; Uchida Y
    J Thromb Thrombolysis; 1997; 4(2):293-300. PubMed ID: 10639273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Arterial thrombosis: interaction between the arterial wall, the platelets and the plasma proteins].
    Bourgain RH; Potvliege P; Derwael E; Six F
    Acta Clin Belg; 1975; 30(3):159-66. PubMed ID: 1231453
    [No Abstract]   [Full Text] [Related]  

  • 39. Our experience of coronary angiography with and without heparin.
    Datta G; Dasbiswas A; Bannerjee A; Majumder B; Sarkar A; Mukherjee D
    Indian Heart J; 2012; 64(4):394-6. PubMed ID: 22929823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of defibrase on arterial thrombus formation.
    Bourgain RH; Six F
    Thromb Res; 1975 Feb; 6(2):195-200. PubMed ID: 1114485
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.